Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
46.51%
median of 389 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Acumen Pharmaceuticals, Inc.
Market Cap
$153.84M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$152.45M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$152.16M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-29.98%
Market Cap
$162.82M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
1.51%
Market Cap
$142.49M
Gross Margin
62.53%
TTM Avg
65.36%
3Y Avg
65.75%
5Y Avg
64.06%
Market Cap
$142.11M
Gross Margin
81.26%
TTM Avg
40.63%
3Y Avg
20.32%
5Y Avg
13.54%
Market Cap
$134.74M
Gross Margin
57.63%
TTM Avg
59.89%
3Y Avg
61.87%
5Y Avg
62.78%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | $153.84M | 0.00% | 0.00% | 0.00% | 0.00% |
| Anavex Life Sciences Corp. (AVXL)vs › | $152.45M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $152.16M | 0.00% | 0.00% | 0.00% | -29.98% |
| Codexis, Inc. (CDXS)vs › | $149.51M | 83.71% | 79.64% | 78.40% | 78.75% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $162.82M | 0.00% | 0.00% | 0.00% | 1.51% |
| Fortress Biotech, Inc. (FBIOP)vs › | $142.49M | 62.53% | 65.36% | 65.75% | 64.06% |
| Alpha Cognition Inc (ACOG)vs › | $142.11M | 81.26% | 40.63% | 20.32% | 13.54% |
| Freenome, Inc. (FRNM)vs › | $137.29M | N/A | N/A | N/A | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $134.74M | 57.63% | 59.89% | 61.87% | 62.78% |
| Compass Therapeutics, Inc. (CMPX)vs › | $172.99M | 0.00% | 50.00% | 25.00% | 16.67% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | -211.85% |
| 2020-09-30 | -310.14% |
| 2020-06-30 | -1176.16% |
| 2020-03-31 | -807.08% |
